Europe Rapid Diagnostics Market 2024-2030

    In Stock




    A rapid diagnostic test (RDT) is a quick and simple medical diagnostic test. RDTs are appropriate for first or emergency medical screening, as well as usage in medical institutions with minimal resources. They also enable point-of-care testing in primary care for items that were previously only measured by laboratory tests. They deliver same-day results within two hours, usually in less than 20 minutes. 


    A rapid test is defined by the European Union as a qualitative or semi-quantitative in vitro-diagnostic medical device used single or in a small series that involves non-automated operations and is meant to provide a quick response.


    Similar to pregnancy tests, lateral flow tests are arguably the most well-known sort of fast diagnostic test, but alternative techniques, like dipsticks, vertical flow, etc. Anything that can be utilized at the patient’s bedside (point of care). The Cornell FeverPhone, an emerging lateral flow device, has been verified to identify causes of acute febrile disease such as Dengue Virus, Chikungunya Virus, and Malaria in around 15 minutes using a single drop of blood.


    A rapid diagnostic test (RDT) based on antigen detection detects the presence of viral proteins, i.e., antigens produced by the COVID-19 virus, in a sample from a person’s respiratory tract within 30 minutes. When appropriate quantities of target antigens are present in the sample, they will bind to particular antibodies attached to one line of paper strip contained in a plastic covering and exhibit a visually visible signal within half an hour in general.


    The viral antigens are expressed and identified by RDT while the virus is actively replicating. This test is most useful for detecting acute or early infection.The test’s accuracy is determined by a variety of parameters, including the period since infection began, viral loads, the quality of sample collection and processing, and the optimisation of chemicals inside test kits.


    Because COVID-19 is a respiratory illness, similar to influenza, and infected individuals have comparable amounts of influenza virus in respiratory samples as found in COVID-19, the sensitivity of this test may vary. According to the literature, such tests may result in a false negative for half or more of COVID-19 infected patients, depending on the group chosen for testing.


    For confirmation, the correctness of these results must be double-checked. Another disadvantage of these tests is that they may provide false-negative results, indicating that the patient is normal but the result is positive owing to detection of other coronaviruses causing common colds other than SARS-CoV-2 by the antibodies contained inside the strip. With the limited evidence now available, WHO does not advocate the use of antigen-detecting RDTs for patient care, however study into their performance and potential diagnostic usefulness is strongly encouraged.


    POC testing (POCT) is a fast diagnostic test that is conducted at or near the site of patient treatment. According to the World Health Organisation (WHO), a POC device must meet the following criteria: it must be inexpensive, sensitive, specific, and user-friendly.


    LF is a well-established technology with numerous advantages, including: rapid qualitative or semiquantitative tests; ease of use (results can be interpreted by untrained personnel); use for in-field applications in remote areas where high-tech equipment is not available; (prolonged shelf-life (about 1 year) and often without refrigeration; small volumes required; relatively low-cost production; good sensitivity and specificity; and possibility of integration with other technologies).


    Despite the benefits mentioned, LF technology has limitations, particularly in terms of reproducibility and sensitivity, such as (1) limited volume around the microliter level; (2) higher volumes that may deteriorate the strip and delay the assay time; (3) pretreatment required for nonliquid samples and a filter must be added to the strip; and (4) integration with electronic/electrochemical systems.





    infographic:Europe Rapid Diagnostics Market , Europe Rapid Diagnostics Market Size, Europe Rapid Diagnostics Market Trend, Europe Rapid Diagnostics Market ForeCast, Europe Rapid Diagnostics Market Risks, Europe Rapid Diagnostics Market Report, Europe Rapid Diagnostics Market Share

    QuantuMDx Group Limited, a UK-based producer of transformative point-of-care diagnostics, has announced the release of Q-POC, a quick, PCR point-of-care diagnostic device.


    QuantuMDx’s Q-POC system and its first test, a SARS-CoV-2 detection assay, were CE-IVD approved under the In Vitro Diagnostics Directive (98/79/EC) and will be available at ECCMID.


    The Q-POC SARS-CoV-2 assay was studied at St George’s, University of London, to compare clinical performance to existing assays. According to the Development and Assessment of Rapid Technology (DART) Study, the sensitivity specificity and there is no cross reactivity with common commensal or possibly interfering organisms.


    Q-POC is a portable PCR system that condenses a complete molecular diagnostic laboratory into a single device that is easy to use, accessible, and inexpensive and provides quick molecular diagnostic testing.


    at the point of treatment, with findings in a matter of minutes. Q-POC was created for front-line healthcare providers and may be utilized in a variety of contexts, including emergency departments, intensive care units, maternity centers, clinics, and pharmacies.


    The Q-POC SARS-CoV-2 assay is housed in a sealed, single-use test cassette intended for safety, convenience of use, and contamination prevention. On-board reagents are also lyophilized for storage at room temperature, easier shipment, and a longer shelf life.


    QuantuMDx’s Q-POC SARS-CoV-2 Assay was developed using the most recent sequencing data to assure 100% coverage of all known SARS-CoV-2 sequences.



    • QuantuMDx
    • Avacta
    • Hologic
    • Coris Bioconcept
    • Fujifilm


    1. How many  Europe Rapid Diagnostics Market are manufactured per annum in Europe? Who are the sub-component suppliers in different regions?
    2. Cost breakup of a Europe Rapid Diagnostics Market  and key vendor selection criteria
    3. Where is Europe Rapid Diagnostics Market manufactured? What is the average margin per unit?
    4. Market share of Europe Rapid Diagnostics Market  manufacturers and their upcoming products
    5. Cost advantage for OEMs who manufacture Europe Rapid Diagnostics Market  in-house
    6. 5 key predictions for next 5 years in Europe Rapid Diagnostics Market
    7. Average B-2-B  Europe Rapid Diagnostics Market price in all segments
    8. Latest trends in  Europe Rapid Diagnostics Market, by every market segment
    9. The market size (both volume and value) of the  Europe Rapid Diagnostics Market in 2024-2030 and every year in between?
    10. Production breakup of  Europe Rapid Diagnostics Market, by suppliers and their OEM relationship
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2024-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2024-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2024-2030
    21 Product installation rate by OEM, 2023
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2023
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
      Your Cart
      Your cart is emptyReturn to Shop